For Research Use Only. Not for human consumption. The following summarizes published preclinical literature and analytical data for laboratory research purposes only.
Search “wolverine stack peptide” and you will land on dozens of pages using the name interchangeably for different things. This overview separates the two questions worth answering: where the nickname actually comes from, and what a lot of pre-blended BPC-157/TB-500 research material actually contains when it is independently tested.
Compound Identity: BPC-157 and TB-500
BPC-157 is a synthetic pentadecapeptide — a linear chain of 15 amino acids — with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), molecular formula C62H98N16O22, an average molecular weight of approximately 1,419.5 g/mol, and CAS registry number 137525-51-0 (PubChem CID 9941957). Its sequence corresponds to a partial region of a stable protein first characterized from human gastric juice, which is the source of its full designation, “stable gastric pentadecapeptide BPC 157” (World Journal of Gastroenterology, PMC4717094).
TB-500 is the name used across the research-peptide supply chain for a synthetic analog of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid regulatory protein found in nearly all mammalian cell types and classified as an actin-binding/actin-sequestering protein (Clinical Ophthalmology, PMC2701135). Researchers should be aware that “TB-500” is used inconsistently across suppliers — some list it as the full 43-residue Tβ4 protein and others as a short 7-residue synthetic fragment corresponding to Tβ4’s actin-binding region. Ascenyx Bio’s COA testing identifies the material in this product as Thymosin Beta-4, and buyers relying on exact molecular identity for their own protocols should always confirm against the lot-specific COA rather than the product name alone.
Where the Name “Wolverine Stack” Comes From
“Wolverine Stack” is not a scientific, regulatory, or pharmacopeial term. It is an informal nickname that originated in online biohacking and peptide-research forums during the 2010s, referencing the Marvel Comics character Wolverine, whose fictional “healing factor” is a defining trait of the character. The nickname was attached to the BPC-157/TB-500 pairing because both compounds are independently studied in tissue-repair-adjacent animal and cell-culture models, and the comic-book reference proved memorable enough to become the dominant informal search term for the combination.
This naming history is offered here strictly as an etymology note. It is not a description of any confirmed effect of this product in any organism, and it carries no scientific or regulatory weight. No pharmacopeial body, regulatory agency, or peer-reviewed clinical study defines a “Wolverine Stack” protocol, formulation, or ratio. Ascenyx Bio uses the name only because it is the term researchers search for — the product itself is sold strictly for in-vitro and laboratory research applications, with no representation of any outcome in humans or animals.
Synthesis and Stability Characteristics
Both BPC-157 and TB-500, at these chain lengths, are produced synthetically using standard solid-phase peptide synthesis (SPPS), the conventional method for assembling linear peptide sequences from protected amino acid building blocks. After synthesis, cleavage, and purification (typically by preparative HPLC), the finished peptide is lyophilized — freeze-dried into a stable powder — which is the standard commercial form for research peptides because it substantially extends shelf life compared to material in solution.
Published Research on Each Component
The literature base for these two peptides is independent — each compound has its own body of published animal and in-vitro research, but no published study to date has evaluated BPC-157 and TB-500 administered together as a combination.
For BPC-157, a widely cited rat study found that intramuscular and intragastric administration was associated with significantly reduced gastric ulcer area in a chemically induced injury model (World Journal of Gastroenterology, PMC4717094). Separate rat models of Achilles tendon transection and detachment reported that BPC-157 administration was associated with accelerated tendon-to-bone healing markers, including in a model where it counteracted the healing impairment caused by corticosteroid administration (PubMed, PMID 16583442). A recent narrative review consolidates this tendon/ligament dataset across multiple rodent models while also noting open questions about translational relevance (PMC12446177). Proposed mechanisms in this literature center on modulation of nitric oxide signaling and angiogenesis at injury sites (PMC11768438).
For Thymosin Beta-4, a 2013 rat study in *Regulatory Peptides* examined surgically transected medial collateral ligaments treated with Tβ4 delivered via fibrin sealant, finding more organized collagen fiber structure and significantly higher biomechanical tensile properties in treated tissue at four weeks compared to controls (PubMed, PMID 23523891). A review in *Clinical Ophthalmology* separately consolidates corneal and dermal wound-healing animal models in which Tβ4 was associated with accelerated re-epithelialization and reduced post-injury inflammation (PMC2701135). Proposed mechanisms center on Tβ4’s role as an actin-sequestering protein that is thought to support cell migration to injury sites.
Because each peptide has a distinct proposed mechanism — nitric-oxide/angiogenesis pathways for BPC-157 and actin-mediated cell migration for Tβ4 — combining them in a research context is a hypothesis researchers may wish to test rather than an outcome established in the existing literature.
Analytical Verification: What Our COA Shows
Ascenyx Bio’s BPC-157/TB-500 combination vial (labeled 10mg/10mg, 20mg total) was independently tested by Freedom Diagnostics using HPLC-UV/LC-MS methodology.
| Attribute | Verified result |
|---|---|
| Lot number | AX-BB20-081026-001 |
| Appearance | White lyophilized powder |
| Verified purity | 99.01% |
| BPC-157 content | 12.72 mg |
| Thymosin Beta-4 content | 10.73 mg |
| Total verified content | 23.45 mg |
| Label claim | 20 mg |
| Fill vs. label | +17% over label |
The full lot-specific certificate of analysis is available through our COA library, and researchers who want a walkthrough of how to interpret purity, identity, and mass-spec fields on a COA can reference our guide to reading a peptide certificate of analysis.
Research Use Only
This product is supplied as a lyophilized powder intended strictly for in-vitro and laboratory research applications by qualified personnel. This material is not a drug, dietary supplement, or cosmetic product, and it is not intended for human or animal consumption.